\-\ Texto\\:\\ \ \(0\)\
\-\ first\\-line\\ therapy\\ for\\ patients\\ with\\ adpkd\\ typically\\ involves\\ controlling\\ hypertension\\.\\ \\ treating\\ hypertension\\ appears\\ to\\ serve\\ two\\ functions\\.\\ \\ the\\ first\\ is\\ to\\ slow\\ the\\ rate\\ of\\ loss\\ of\\ renal\\ function\\.\\ \\ the\\ second\\ is\\ with\\ controlled\\ hypertension\\ the\\ risk\\ of\\ a\\ rupturing\\ a\\ \\ cerebral\\ aneurysm\\ \\(which\\ these\\ patients\\ are\\ predisposed\\ to\\)\\ \\ is\\ decreased\\.\\ \\ \\ ace\\ inhibitors\\ are\\ currently\\ the\\ anti\\-hypertensive\\ medication\\ of\\ choice\\.\\ \\ patients\\ that\\ develop\\ end\\-stage\\ renal\\ disease\\ will\\ ultimately\\ need\\ dialysis\\ or\\ kidney\\ transplant\\.\ \(0\)\
\-\ multiple\\ bilateral\\ renal\\ cysts\\ consistent\\ with\\ the\\ diagnosis\\ of\\ adult\\ polycystic\\ kidney\\ disease\ \(0\)\
\-\ autosomal\\ dominant\\ \\(adult\\)\\ polycystic\\ kidney\\ disease\\ \\(adpkd\\)\ \(0\)\
\-\ adult\\ polycystic\\ kidney\\ disesase\ \(0\)\
\-\ cystic\\ renal\\ dysplasia\ \(5\)\
\-\ nephronophthisis\ \(0\)\
\-\ acquired\\ cystic\\ kidney\\ disease\ \(0\)\
\-\ 26\\ year\\ of\\ african\\ american\\ male\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ kidney\\:\\ 0\\.3367027934338258\ \(0\)\
\-\ polycystic\\:\\ 0\\.3040503386640863\ \(0\)\
\-\ adult\\:\\ 0\\.26524994798834145\ \(0\)\
\-\ renal\\:\\ 0\\.23876261711726665\ \(0\)\
\-\ adpkd\\:\\ 0\\.2327388182359383\ \(0\)\
\-\ hypertension\\:\\ 0\\.2200235021090996\ \(0\)\
\-\ patients\\:\\ 0\\.16176843000275476\ \(0\)\
\-\ disease\\:\\ 0\\.1609434987868846\ \(0\)\
\-\ disesase\\:\\ 0\\.1532905400284259\ \(0\)\
\-\ rupturing\\:\\ 0\\.14647729458665454\ \(0\)\
\-\ nephronophthisis\\:\\ 0\\.14647729458665454\ \(0\)\
\-\ serve\\:\\ 0\\.13789362047249326\ \(0\)\
\-\ first\\:\\ 0\\.1293710588322239\ \(0\)\
\-\ functions\\:\\ 0\\.12801672913142614\ \(0\)\
\-\ controlling\\:\\ 0\\.12624630045903626\ \(0\)\
\-\ inhibitors\\:\\ 0\\.12183765445418698\ \(0\)\
\-\ predisposed\\:\\ 0\\.11943305501726488\ \(0\)\
\-\ ace\\:\\ 0\\.11546088889883681\ \(0\)\
\-\ cystic\\:\\ 0\\.11545854867636073\ \(0\)\
\-\ the\\:\\ 0\\.11475742354116612\ \(0\)\
\-\ of\\:\\ 0\\.11254857987921822\ \(0\)\
\-\ dialysis\\:\\ 0\\.10618418745971439\ \(0\)\
\-\ treating\\:\\ 0\\.1051954593039347\ \(0\)\
\-\ ultimately\\:\\ 0\\.10024178614321283\ \(0\)\
\-\ controlled\\:\\ 0\\.09988801453282653\ \(0\)\
\-\ autosomal\\:\\ 0\\.09886930683149764\ \(0\)\
\-\ transplant\\:\\ 0\\.09586066435553002\ \(0\)\
\-\ slow\\:\\ 0\\.09238881544787521\ \(0\)\
\-\ acquired\\:\\ 0\\.09238881544787521\ \(0\)\
\-\ choice\\:\\ 0\\.09088941734190104\ \(0\)\
\-\ dominant\\:\\ 0\\.08970279287457178\ \(0\)\
\-\ medication\\:\\ 0\\.08859446612975583\ \(0\)\
\-\ develop\\:\\ 0\\.08824069451936954\ \(0\)\
\-\ need\\:\\ 0\\.08824069451936954\ \(0\)\
\-\ african\\:\\ 0\\.08657561748250224\ \(0\)\
\-\ involves\\:\\ 0\\.08340661994768392\ \(0\)\
\-\ american\\:\\ 0\\.08178122068798445\ \(0\)\
\-\ is\\:\\ 0\\.07875035867941794\ \(0\)\
\-\ 26\\:\\ 0\\.07786560043611841\ \(0\)\
\-\ function\\:\\ 0\\.07758475494341553\ \(0\)\
\-\ currently\\:\\ 0\\.07363214487121345\ \(0\)\
\-\ dysplasia\\:\\ 0\\.07341344073196879\ \(0\)\
\-\ aneurysm\\:\\ 0\\.07298439110471047\ \(0\)\
\-\ are\\:\\ 0\\.07274405267703452\ \(0\)\
\-\ rate\\:\\ 0\\.07263503276574103\ \(0\)\
\-\ cysts\\:\\ 0\\.07263503276574103\ \(0\)\
\-\ to\\:\\ 0\\.07188952551590168\ \(0\)\
\-\ second\\:\\ 0\\.07175929993422692\ \(0\)\
\-\ appears\\:\\ 0\\.07019359356438233\ \(0\)\
\-\ risk\\:\\ 0\\.06848907292409102\ \(0\)\
\-\ typically\\:\\ 0\\.06729017324924452\ \(0\)\
\-\ cerebral\\:\\ 0\\.06640815284765778\ \(0\)\
\-\ will\\:\\ 0\\.061693847356242865\ \(0\)\
\-\ decreased\\:\\ 0\\.05937359712172353\ \(0\)\
\-\ loss\\:\\ 0\\.05839743705241085\ \(0\)\
\-\ two\\:\\ 0\\.05692299495844515\ \(0\)\
\-\ with\\:\\ 0\\.0563079138144386\ \(0\)\
\-\ therapy\\:\\ 0\\.05507402598771902\ \(0\)\
\-\ these\\:\\ 0\\.054128430210967936\ \(0\)\
\-\ consistent\\:\\ 0\\.05197394307199987\ \(0\)\
\-\ bilateral\\:\\ 0\\.05151518317351447\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04968975107779647\ \(0\)\
\-\ multiple\\:\\ 0\\.04688401042325718\ \(0\)\
\-\ which\\:\\ 0\\.04358551915256092\ \(0\)\
\-\ male\\:\\ 0\\.04267764496217947\ \(0\)\
\-\ that\\:\\ 0\\.04159680430755338\ \(0\)\
\-\ or\\:\\ 0\\.033345709783599825\ \(0\)\
\-\ year\\:\\ 0\\.02954014727649798\ \(0\)\
\-\ for\\:\\ 0\\.029052446210654965\ \(0\)\
